Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 22.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,841,151 shares of the company’s stock after selling 1,120,356 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Teva Pharmaceutical Industries were worth $119,882,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Phoenix Financial Ltd. increased its position in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. Finally, Rubric Capital Management LP lifted its position in shares of Teva Pharmaceutical Industries by 1.8% during the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock worth $435,760,000 after purchasing an additional 450,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares in the company, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,127,018 shares of company stock worth $37,298,712. Insiders own 0.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on TEVA shares. Piper Sandler reiterated an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Scotiabank increased their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $35.33 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The firm has a market capitalization of $40.62 billion, a P/E ratio of 26.56, a P/E/G ratio of 3.51 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company’s fifty day moving average price is $31.51 and its 200 day moving average price is $30.40.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.